Medscape |
CANVAS: Experts Spar on Canagliflozin Risk/Benefit in Diabetes
Medscape SAN DIEGO — The CANVAS program trial results with canagliflozin may have confirmed that cardiovascular benefit is likely to be a class effect of the sodium-glucose cotransporter 2 (SGLT2) inhibitors for type 2 diabetes, but the extent to which the ... |
Social Plugin